Following the presentation titled ‘Discovering Targeted Glue™ degraders with Amphista's Eclipsys® platform’, Simon Gilbert, PhD, Presenting Author and Associate Director Discovery Biology at Amphista ...

Amazon's new pay model rewards top performers, cuts first-time achievers The revised structure places greater emphasis on an employee's rating history rather than just current performance.

Leveraging deep expertise in ubiquitin biology and E3 ligase structure, SEED developed a novel RBM39 degrader ... high drug concentrations due to excessive binary complex formation. VHL-based PROTACs ...

Most employees typically fall into the "Significant Impact" category. Under the new structure, managers will be allowed to assign the coveted "Outstanding Impact" rating to more employees ...

A colossal structure in the distant Universe is defying our understanding of how the Universe evolved. In light that has traveled for 6.9 billion years to reach us, astronomers have found a giant ...

KraneShares Eltc Vhl and Ft Mbly ETF earns a Below Average ... The team is bolstered by the fund's structure. It tracks an index, which is helpful because historical data, such as Morningstar's ...

Astronomers have discovered what may be the largest-scale structure in the known universe — a group of galaxy clusters and clusters of galaxy clusters that spans roughly 1.3 billion light-years ...

Innovative Eclipsys® platform enables rational design of novel Targeted Glues with superior drug-like properties Cambridge, UK, 22 May 2025 - Amphista Therapeutics, a leader in the discovery of next-g ...

When you first enter a new world, you can either spawn near a structure or find one while exploring any of the three dimensions. While finding some can be quite easy, others are extremely hard to ...

WELIREG was approved in the US in August 2021 for similar indications. The open-label trial enrolled 61 subjects with VHL-associated RCC and demonstrated an ORR of 49% with all responses being ...

The enzyme KRas has become a popular cancer target for drugmakers in the last decade, with many companies developing small molecules that inhibit one or multiple KRas mutants. Now, scientists are ...